HROW vs. HALO

Last updated Apr 2, 2026

Compare and contrast key facts about Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO).

Performance

HROW vs. HALO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). The values are adjusted to include any dividend payments, if applicable.

HROW vs. HALO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HROW Harrow Health, Inc.	-27.69%	46.05%	199.55%	-24.12%	70.83%	25.95%	-11.83%	36.73%	234.71%	-32.00%
HALO Halozyme Therapeutics, Inc.	-2.82%	40.77%	29.36%	-35.04%	41.51%	-5.85%	140.89%	21.19%	-27.79%	105.06%

Fundamentals

EPS HROW : -$0.20 HALO : $2.61
PS Ratio HROW : 3.37 HALO : 5.68
Total Revenue (TTM) HROW : $272.30M HALO : $1.40B
Gross Profit (TTM) HROW : $204.37M HALO : $1.17B
EBITDA (TTM) HROW : $36.50M HALO : $590.37M

Returns By Period

In the year-to-date period, HROW achieves a -27.69% return, which is significantly lower than HALO's -2.82% return. Over the past 10 years, HROW has outperformed HALO with an annualized return of 24.53%, while HALO has yielded a comparatively lower 20.96% annualized return.

HROW

• 1D: 0.48%
• 1M: -33.89%
• YTD: -27.69%
• 6M: -26.75%
• 1Y: 41.83%
• 3Y*: 18.75%
• 5Y*: 39.16%
• 10Y*: 24.53%

HALO

• 1D: 1.19%
• 1M: -6.37%
• YTD: -2.82%
• 6M: -12.73%
• 1Y: 5.71%
• 3Y*: 19.64%
• 5Y*: 9.04%
• 10Y*: 20.96%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HROW vs. HALO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HROW

HROW Risk / Return Rank: 61
HROW Sharpe Ratio Rank: 63
HROW Sortino Ratio Rank: 62
HROW Omega Ratio Rank: 61
HROW Calmar Ratio Rank: 60
HROW Martin Ratio Rank: 61

HALO

HALO Risk / Return Rank: 43
HALO Sharpe Ratio Rank: 45
HALO Sortino Ratio Rank: 40
HALO Omega Ratio Rank: 43
HALO Calmar Ratio Rank: 42
HALO Martin Ratio Rank: 43

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HROW vs. HALO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Harrow Health, Inc. (HROW) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HROW	HALO	Difference
Sharpe ratio Return per unit of total volatility	0.65	0.13	+0.52
Sortino ratio Return per unit of downside risk	1.28	0.47	+0.81
Omega ratio Gain probability vs. loss probability	1.17	1.08	+0.09
Calmar ratio Return relative to maximum drawdown	0.85	0.08	+0.77
Martin ratio Return relative to average drawdown	2.19	0.17	+2.02
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HROW vs. HALO - Sharpe Ratio Comparison

The current HROW Sharpe Ratio is 0.65, which is higher than the HALO Sharpe Ratio of 0.13. The chart below compares the historical Sharpe Ratios of HROW and HALO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HROW	HALO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.65	0.13	+0.52
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.56	0.23	+0.33
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.35	0.48	-0.14
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	0.23	-0.27

Correlation

The correlation between HROW and HALO is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HROW vs. HALO - Dividend Comparison

Neither HROW nor HALO has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

HROW vs. HALO - Drawdown Comparison

The maximum HROW drawdown since its inception was -99.46%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for HROW and HALO.

Drawdown Indicators

	HROW	HALO	Difference
Max Drawdown Largest peak-to-trough decline	-99.46%	-74.26%	-25.20%
Max Drawdown (1Y) Largest decline over 1 year	-39.27%	-31.69%	-7.58%
Max Drawdown (5Y) Largest decline over 5 years	-71.15%	-49.06%	-22.09%
Max Drawdown (10Y) Largest decline over 10 years	-71.15%	-49.06%	-22.09%
Current Drawdown Current decline from peak	-74.33%	-19.49%	-54.84%
Average Drawdown Average peak-to-trough decline	-86.86%	-32.02%	-54.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.16%	14.78%	+0.38%

Volatility

HROW vs. HALO - Volatility Comparison

Harrow Health, Inc. (HROW) has a higher volatility of 15.62% compared to Halozyme Therapeutics, Inc. (HALO) at 9.11%. This indicates that HROW's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HROW	HALO	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.62%	9.11%	+6.51%
Volatility (6M) Calculated over the trailing 6-month period	52.39%	23.48%	+28.91%
Volatility (1Y) Calculated over the trailing 1-year period	64.92%	43.82%	+21.10%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	70.23%	39.51%	+30.72%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	70.70%	43.38%	+27.32%

Financials

HROW vs. HALO - Profitability Comparison

The chart below illustrates the profitability comparison between Harrow Health, Inc. and Halozyme Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HROW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported a gross profit of 70.62M and revenue of 89.09M. Therefore, the gross margin over that period was 79.3%.

HALO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported a gross profit of 373.00M and revenue of 451.77M. Therefore, the gross margin over that period was 82.6%.

HROW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported an operating income of 15.59M and revenue of 89.09M, resulting in an operating margin of 17.5%.

HALO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported an operating income of -92.89M and revenue of 451.77M, resulting in an operating margin of -20.6%.

HROW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Harrow Health, Inc. reported a net income of 6.63M and revenue of 89.09M, resulting in a net margin of 7.4%.

HALO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Halozyme Therapeutics, Inc. reported a net income of -141.59M and revenue of 451.77M, resulting in a net margin of -31.3%.